3 In humans, inhaled albuterol is supported as a first-line therapy for acutely managing hyperkalemia, with the treatment lowering potassium concentrations within 15 to 30 minutes of administration.

Patients were excluded if they had a history of hypersensitivity to albuterol or levalbuterol, required β-adrenergic-receptor antagonist therapy, or had acute respiratory decompensation requiring ...

In patients with baseline tachycardia, the mean largest HR increase was 1.4 beats/min (1.3%) with albuterol and 2.0 beats/min (2.1%) with levalbuterol (both increases were not significant).